证券代码：301230 证券简称：泓博医药 公告编号：2024-061 上海泓博智源医药股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 截至 2024 年 8 月 31 日，公司通过回购专用证券账户以集中竞价交易方式已累计回 购股份 2,046,200 股，占公司目前总股本 139,586,605 股的比例为 1.4659%，最高成交价 为 37.68 元/股，最低成交价为 19.78 元/股，成交总金额为 53,075,305.42 元（不含交易 费用）。 上述回购资金来源为公司自有资金，本次回购符合相关法律法规及公司既定回购股 份方案的要求。 上海泓博智源医药股份有限公司（以下简称"公司"）于 2024 年 2 月 7 日召开第三 届董事会第十四次会议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议 案》，同意公司以自有资金采取集中竞价交易方式回购公司股份用于实施股权激励或员 工持股计划，回购资金总额不低于人民币 5,000 万元（含）且不超过人民币 10,000 万元 （含），回购股份的价格不超过人民币 ...

证券代码：301230 证券简称：泓博医药 公告编号：2024-060 上海泓博智源医药股份有限公司 股东减持计划的预披露公告 1、减持目的：自身资金需求 公司股东北京中富基石投资中心（有限合伙）保证向本公司提供的信息内容 真实、准确、完整，没有虚假记载、误导性陈述或者重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 截至本公告披露日，北京中富基石投资中心（有限合伙）（以下简称"中富基石"） 持有上海泓博智源医药股份有限公司（以下简称"公司"或"本公司"）6,164,860 股，占公 司扣除最新披露的回购专户股份后总股本比例 4.48%，与一致行动人北京中富成长股权 投资中心（有限合伙）合计持有公司 8,967,660 股，占公司扣除最新披露的回购专户股 份后总股本比例 6.52%。中富基石计划在本公告发布之日起 15 个交易日后的 3 个月内 以集中竞价和大宗交易方式减持公司股份不超过 1,370,000 股，即减持比例不超过公司 扣除最新披露的回购专户股份后总股本的 1.00%，其中通过集中竞价交易方式减持公司 股份不超过 685,000 股，不超过扣除公司回购专 ...

Investment Rating - Buy/Maintain rating for Hongbo Pharmaceutical (301230) with a target price of 19.74 [1] Core Views - Revenue growth remains stable, with significant quarter-over-quarter improvement in orders [1] - Q2 2024 revenue increased by 16.15% YoY to 135 million RMB, while net profit attributable to shareholders decreased by 30.11% YoY to 12 million RMB [3] - New orders in the service sector increased by 42.42% QoQ to 165 million RMB, and new orders in the commercial production sector increased by 41.99% QoQ to 91 million RMB [3] - Drug discovery business grew steadily, with revenue increasing by 14.75% YoY to 158 million RMB, while commercial production business revenue surged by 72.31% YoY to 79 million RMB [3] - R&D investment continues to grow, with R&D expenses increasing by 18.33% YoY to 22.82 million RMB in 2023, and the PR-GPT platform is expected to be commercially operational by Q4 2024 [3] Financial Forecasts - Revenue for 2024-2026 is projected to be 592/722/888 million RMB, with YoY growth rates of 20.89%/21.95%/23.07% [3][4] - Net profit attributable to shareholders for 2024-2026 is expected to be 34/50/74 million RMB, with YoY growth rates of -9.45%/45.33%/48.93% [3][4] - PE ratios for 2024-2026 are forecasted at 81/56/37 times [3][4] Business Performance - Drug discovery business achieved a gross margin of 33.17%, down 2.35 percentage points YoY [3] - Process research and development business revenue decreased by 51.47% YoY to 22 million RMB, with a gross margin of 7.28%, down 34.35 percentage points YoY [3] - Commercial production business achieved a gross margin of 3.47%, down 22.55 percentage points YoY [3] R&D and Technology - The company has 675 R&D personnel, accounting for 66.70% of total employees [3] - The CADD/AIDD technology platform has served 69 new drug projects, with 5 in Phase I clinical trials and 2 in the clinical application stage [3] Market Performance - Total market capitalization is 2.755 billion RMB, with a total share capital of 140 million shares [3] - The stock price reached a 12-month high of 54.99 RMB and a low of 19.68 RMB [3]

一、监事会会议召开情况 上海泓博智源医药股份有限公司（以下简称"公司"）第三届监事会第十二次会议 通知于 2024 年 8 月 16 日以邮件形式送达全体监事。会议于 2024 年 8 月 26 日上午 11:00 以现场结合通讯会议的方式召开。本次会议由监事会主席刘国东先生主持召开， 应出席监事 5 名，实际出席 5 名。会议召开及表决程序符合《中华人民共和国公司法》 及《上海泓博智源医药股份有限公司章程》的有关规定。 二、监事会会议审议情况 经出席会议的全体监事认真审议，通过了如下议案： 证券代码：301230 证券简称：泓博医药 公告编号：2024-056 上海泓博智源医药股份有限公司 第三届监事会第十二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 经审核，监事会认为：公司 2024 年中期利润分配方案符合《公司法》、《上市 公司监管指引第 3 号——上市公司现金分红》等法律法规、规范性文件及《公司章 程》、《公司未来三年股东分红回报规划》的相关规定，符合公司目前的实际情况和 利润分配政策，有利于保障公司生产经营的正常运行，不存在损害其 ...

上海泓博智源医药股份有限公司 证券代码：301230 证券简称：泓博医药 公告编号：2024-058 关于公司 2024 年中期利润分配方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 上海泓博智源医药股份有限公司(以下简称"公司")于2024年8月26日召开了第三届 董事会第十八次会议、第三届监事会第十二次会议，审议通过了《关于公司2024年中期 利润分配方案的议案》，现将有关情况公告如下： 一、利润分配方案的基本情况 公司合并报表 2024 年上半年实现归母净利润 15,976,491.16 元，母公司 2024 年上 半年实现净利润 32,035,790.63 元。截至 2024 年 6 月 30 日，母公司累计未分配利润为 115,997,835.88 元，合并报表未分配利润为 167,111,549.95 元，上述数据尚未经审计。按 照合并报表、母公司报表中可供分配利润孰低的原则，公司可供分配的利润以母公司报 表期末未分配利润为依据。 为积极回报股东，根据中国证监会鼓励分红的有关规定以及《公司章程》中关于利 润分配政策的要求，在保证公司健康 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥265,763,514.46, representing an increase of 11.83% compared to ¥237,655,059.97 in the same period last year[12]. - Net profit attributable to shareholders decreased by 51.42% to ¥15,976,491.16 from ¥32,888,192.76 year-on-year[12]. - The net profit after deducting non-recurring gains and losses fell by 71.70% to ¥9,375,344.43 compared to ¥33,129,669.16 in the previous year[12]. - The net cash flow from operating activities was negative at -¥21,592,117.20, a decline of 159.81% from ¥36,101,708.31 in the same period last year[12]. - Basic and diluted earnings per share decreased by 54.17% to ¥0.11 from ¥0.24 year-on-year[12]. - The weighted average return on net assets was 1.43%, down from 2.91% in the previous year[12]. - Total assets at the end of the reporting period were ¥1,411,180,265.68, a decrease of 5.11% from ¥1,487,163,922.77 at the end of the previous year[12]. - Net assets attributable to shareholders decreased by 4.88% to ¥1,062,956,605.92 from ¥1,117,544,666.53 at the end of the previous year[12]. Research and Development - Research and development (R&D) expenses for the first half of 2024 amounted to 2,281.86 million, representing an 18.33% increase compared to 1,928.42 million in the first half of 2023[32]. - R&D expenses accounted for 8.59% of total revenue in the first half of 2024, compared to 8.11% in the same period of 2023[31]. - The cumulative R&D investment from 2022 to the first half of 2024 showed a compound annual growth rate (CAGR) of 27.81%[35]. - The company has established a strong intellectual property portfolio with 39 patents granted, including 38 domestic patents and 1 U.S. patent[36]. - The company focuses on expanding its service offerings by integrating drug chemistry and synthetic chemistry to enhance process research and development[30]. - The company has developed various antiviral compounds and key intermediates, showcasing its focus on innovative drug development[1]. Market and Competitive Landscape - The company faces intensified competition in the CRO market, with major players like WuXi AppTec and Kanglong Chemical increasing their market presence, which may impact the company's market share and profitability[95]. - The primary product, Ticagrelor and its key intermediates, accounted for 86.13% of the commercial production revenue in the first half of 2024, indicating a risk of revenue concentration[98]. - The company is at risk of declining gross margins due to rising labor costs and increased competition in the CRO sector, despite efforts to enhance efficiency[96]. - The company is actively expanding its domestic market presence, although it faces challenges due to late entry and increasing competition[99]. Environmental Compliance - The company is classified as a key pollutant discharge unit by the Shanghai environmental protection authority, indicating a commitment to compliance with environmental regulations[109]. - The company has reported a total nitrogen discharge of 2.29 mg/L from its wastewater treatment facilities, meeting the required standards[112]. - The company has established dedicated hazardous waste storage facilities that comply with safety and environmental standards, including leak-proof and ventilation measures[120]. - The company has achieved ISO 14001 and ISO 45001 certifications for its environmental management and occupational health and safety management systems[126]. - The company has taken measures to reduce carbon emissions through green pharmaceutical technologies and energy-saving initiatives[126]. Corporate Governance and Shareholder Rights - The company maintains a strong commitment to shareholder rights and corporate governance, ensuring compliance with relevant laws and regulations[127]. - The company has not reported any changes in its board of directors, supervisors, or senior management during the reporting period[105]. - The company has no significant related party transactions other than daily operational transactions[140]. - The company has no violations regarding external guarantees during the reporting period[130]. Future Strategies - The company emphasizes the importance of risk awareness in its future plans and strategies[2]. - The company’s future strategies include potential market expansion and new product development[2]. - The company aims to enhance its market position by optimizing production capacity and integrating industry chain resources to create new profit growth points[101]. - The company is focused on enhancing its competitive edge through continuous innovation and technology upgrades[41].

证券代码：301230 证券简称：泓博医药 公告编号：2024-059 上海泓博智源医药股份有限公司 关于部分募投项目延期的公告 上海泓博智源医药股份有限公司（以下简称"公司"）于 2024 年 8 月 26 日召开的第三 届董事会第十八次会议及第三届监事会第十二次会议，审议通过《关于部分募投项目延期 的议案》，同意公司在募集资金投资项目（以下简称"募投项目"）实施主体、募集资金投 资用途及规模不发生变更的情况下，对部分募投项目进行延期。本次部分募投项目延期事 项在董事会审批权限范围内，无需提交股东大会审议。现将具体情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意上海泓博智源医药股份有限公司首次公开发 行股票注册的批复》（证监许可〔2022〕1443 号）同意注册，公司向社会公开发行人民 币普通股 1,925 万股，共计募集资金人民币 77,000.00 万元，扣除发行相关费用合计人民 币 8,415.16 万元，实际募集资金净额为人民币 68,584.84 万元。上述募集资金到位情况 业经立信会计师事务所（特殊普通合伙）验证，并由其出具《验资报告》（信会师报字 [2022]第 ZA1 ...

| 非经营性资金占用 | 资金占用方 | 占用方与上 | 上市公司核算 | 2024年期初 | 2024年半年度 | 2024年半年度 | 2024年半年 | 2024年半年 | 占用形 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 名称 | 市公司的关 | 的会计科目 | 占用资金余 | 占用累计发生 | 占用资金的利 | 度偿还累计 | 度期末占用 | 成原因 | | | | | 联关系 | | 额 | 金额（不含利 | 息 | 发生金额 | 资金余额 | | | | | | | | | 息） | （如有） | | | | | | 控股股东、实际控制人 | | | | | | | | | | | | 及其附属企业 | | | | | | | | | | | | 小计 | - | - | - | | | | | | | - | | 前控股股东、实际控制 | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | 小计 | - | - | - ...

中信证券股份有限公司 关于上海泓博智源医药股份有限公司 部分募投项目延期的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"）作为上海泓博 智源医药股份有限公司（以下简称"泓博医药"或"公司"）首次公开发行股票并在 深圳证券交易所创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》 《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《深 圳证券交易所创业板股票上市规则》等相关规定，对公司此次拟延期募投项目的 事项进行了核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意上海泓博智源医药股份有限公司首次 公开发行股票注册的批复》（证监许可〔2022〕1443 号）同意注册，公司向社会 公开发行人民币普通股 1,925 万股，共计募集资金人民币 77,000.00 万元，扣除 发行相关费用合计人民币 8,415.16 万元，实际募集资金净额为人民币 68,584.84 万元。上述募集资金到位情况业经立信会计师事务所（特殊普通合伙）验证，并 由其出具《验资报告》（信会师报字 ...

上海泓博智源医药股份有限公司（以下简称"公司"或"本公司"）于 2024 年 4 月 29 日披露了《关于持股 5%以上股东减持计划的预披露公告》（公告号 2024-029），鼎泰 海富投资管理有限公司（以下简称"鼎泰海富"）计划在减持计划发布之日起 15 个交易 日后的 3 个月内（即 2024 年 5 月 24 日-2024 年 8 月 23 日）以集中竞价交易方式减持公 司股份不超过 1,069,900 股，即减持比例不超过公司扣除最新披露的回购专户股份后总 股本的 1.00%（如遇派发现金红利、送股、转增股本、增发新股等除权除息事项，上述 拟减持股份数量将相应进行调整，但减持股份占公司总股本的比例不变）。 公司于 2024 年 6 月 21 日完成了 2023 年年度权益分派实施，股本增加至 139,586,605 股，股东鼎泰海富可减持公司股份数量同步调整为不超过 1,385,100 股，即减持比例不 超过公司扣除最新披露的回购专户股份后总股本的 1.00%。 公司于近日收到鼎泰海富出具的《关于股份减持计划时间届满暨减持结果告知函》， 截至本公告披露日，上述股东本次减持计划时间已届满。根据《上市公司 ...